Relmada Therapeutics, Inc. (RLMD)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Relmada Therapeutics, Inc. (RLMD)
Go deeper and ask any question about RLMD
Company Performance
Current Price
as of Sep 13, 2024$3.09
P/E Ratio
N/A
Market Cap
$93.24M
Description
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Metrics
Overview
- HQCoral Gables, FL
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerRLMD
- Price$3.09-5.50%
Trading Information
- Market Cap$93.24M
- Float83.37%
- Average Daily Volume (1m)139,837
- Average Daily Volume (3m)126,832
- EPS-$2.88
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$17.77M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$18.82M
- EV$20.09M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Earnings Calls